Clinical Judgment Essential in Defining Anemia in Myelofibrosis

In a recent discussion, Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center addressed the important distinction between anemia predominant and symptom predominant myelofibrosis, emphasizing that defining anemia requires clinical judgment rather than strict numerical criteria.

Dr Rampal explained that anemia cannot be defined by hemoglobin numbers alone because its impact varies significantly from patient to patient. He illustrated this point by describing two hypothetical patients both with a hemoglobin level of nine. One patient might remain active, going to the gym and functioning well in daily life despite the laboratory value. The other patient, who may have underlying heart or lung disease, could find themselves unable to function with that same hemoglobin level.

The key distinction, according to Dr Rampal, lies in what constitutes meaningful anemia for each individual patient. He stressed that clinicians must look beyond the numbers on a laboratory report and consider how the anemia is actually affecting the patient's quality of life and functional capacity. This clinical judgment approach allows physicians to better differentiate between patients whose primary issue is anemia related versus those whose predominant symptoms stem from other aspects of their myelofibrosis.

Dr Rampal urged clinicians to be aware of this important distinction and to think about anemia in the context of each patient's overall health status and daily functioning. Rather than adhering strictly to numerical cutoffs, he advocated for a more nuanced approach that considers the whole patient when making treatment decisions and categorizing disease presentation. This patient centered perspective ensures that treatment strategies align with what matters most to each individual living with myelofibrosis.